Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTern Regulatory News (TERN)

Share Price Information for Tern (TERN)

Share Price is delayed by 15 minutes
Get Live Data
1.20    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.20 (18.182%)
Market Cap: £10.27m
TERN Live PriceLast checked at - London Stock Exchange

Intraday Tern Share Chart

FundamentalVR Fund Raise

31 May 2022 07:00

RNS Number : 3134N
Tern PLC
31 May 2022
Β 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014 (WHICH FORMS PART OF DOMESTIC UK LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018). UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE WITHIN THE PUBLIC DOMAIN.

31 May 2022

Β 

Tern Plc

("Tern" or the "Company")

Β 

FundamentalVR Fund Raise

Β 

Tern Plc (AIM:TERN), the company focused on value creation from Internet of Things ("IoT") technology businesses, is pleased to announce that FVRVS Limited ("FundamentalVR"), has undertaken a Series B fund raising round, securing Β£7 million in new equity investment (the "FundamentalVR Series B") from existing investors and a new institutional investor, at a valuation uplift of 77% from the previous book valuation of Tern's holding.

Β 

Highlights

Β 

Β· FundamentalVR has raised a total of Β£7 million in a Series B fund raising from existing investors and a new institutional investor, with an additional Β£1.2 million of convertible loan notes being converted

Β 

Β· Tern has converted approximately Β£570,000 in loan notes and accrued interest it held in FundamentalVR into equity, in line with the terms of these loan notes, but will invest no new money in the FundamentalVR Series B

Β 

Β· The FundamentalVR Series B is intended to provide FundamentalVR with funding to enable to grow in line with its strategy, including expanding its US activities

Β 

Β· With the completion of the Β£7 million FundamentalVR Series B, including the conversion of Tern's loan notes to equity, Tern will hold 20.0% of FundamentalVR's equity, valued at Β£6.3 million at the valuation implied by the FundamentalVR Series B price

Β 

FundamentalVR Fund Raise

Β 

Prior to the FundamentalVR Series B, Tern had a holding of 26.9% in FundamentalVR, plus a loan convertible into FundamentalVR equity of Β£530,000 and accrued interest of Β£39,932. As at 31 December 2021, the date of Tern's last published book valuation, this holding had an audited book value of Β£3.6 million.Β 

Β 

Following the FundamentalVR Series B funding of Β£7 million, the conversion of Tern's Β£0.53 million of loan notes and the conversion of Β£0.63 million of loan notes held by other investors, FundamentalVR is now valued in total at approximately Β£23 million on a pre-money basis and Tern now has a holding of 20.0% in FundamentalVR (before any dilution on exercise of any future FundamentalVR employee share options), with an unaudited book valuation of Β£6.3 million, representing a 77% uplift on the 31 December 2021 book value of Tern's holding.

Β 

Further information on FundamentalVR

Β 

FundamentalVR delivers virtual reality haptic 'flight simulators' for surgery creating a safe, measurable and repeatable space to refine skills. FundamentalVR's goal is to transform the way surgeons prepare, practice, and refine their skills. It has built an immersive, surgical simulation application platform, Fundamental Surgery, to provide medical professionals with the opportunity to rehearse, practice, and test themselves within a safe, controllable space that is as close to real-life as possible.

Β 

According to the latest filed financial statements for FundamentalVR, for the 12 month period ended 31 December 2020, the business recorded an increase in retained unaudited losses of Β£2.12 million and at that date had unaudited net assets of approximately Β£1.27 million. Given the historic nature of these figures Tern does not consider this to be representative of the current business and trading performance of FundamentalVR.

Β 

Further information on FundamentalVR may be found at: https://www.fundamentalvr.com

Β 

Enquiries

Β 

Tern Plc

Al Sisto (CEO)

Sarah Payne (CFO)

via IFC Advisory

Β 

Allenby Capital Limited

(Nominated Adviser and Broker)

David Worlidge / Alex Brearley (Corporate Finance)

Matt Butlin / Kelly Gardiner (Sales and Corporate Broking)

Β 

Tel: 0203 328 5656

Β 

IFC Advisory

(Financial PR and IR)

Tim Metcalfe

Graham Herring

Florence Chandler

Β 

Tel: 0203 934 6630

tern@investor-focus.co.uk

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
MSCBKKBDKBKBCPN
Date   Source Headline
16th Dec 20247:01 amRNS-ROnline Investor Presentation and Q&A Session
16th Dec 20247:00 amRNSPlacing to raise £400,000
1st Nov 20247:00 amRNSDirector/PDMR Shareholding
29th Oct 20247:00 amRNSBoard Changes
25th Oct 20248:27 amRNSFurther re. Wyld Networks Rights Issue
15th Oct 20247:00 amRNSPlacing to raise £625,000
30th Sep 20245:04 pmRNSTotal Voting Rights
30th Sep 20247:00 amRNSDevice Authority Update
23rd Sep 202411:13 amRNSReplacement: Results of Open Offer
23rd Sep 202411:10 amRNSResult of General Meeting
23rd Sep 20247:00 amRNSResults of Open Offer
5th Sep 20247:00 amRNSOpen Offer and Notice of General Meeting
5th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
2nd Sep 202410:16 amRNSStatement re Wyld Networks Rights Issue
9th Aug 20247:00 amRNSPartial sale of Device Authority holding
27th Jun 202412:00 pmRNSResult of AGM
31st May 20245:00 pmRNSTotal Voting Rights
30th May 20247:00 amRNSResults for the year ended 31 December 2023
15th May 20247:00 amRNSExercise of Warrants
3rd May 20247:45 amRNSFurther re. Wyld Networks Warrant Exercise Process
30th Apr 20245:00 pmRNSTotal Voting Rights
25th Apr 20247:00 amRNSExercise of warrants held in Wyld Networks
12th Apr 20247:00 amRNSPlacing to raise £420,000
9th Apr 20247:00 amRNSTalking Medicines record revenue bookings in Q1 24
21st Mar 20247:00 amRNSOnline Investor Presentation and Q&A Session
5th Mar 20247:00 amRNSKonektio Administration
7th Feb 20247:00 amRNSDevice Authority Fund Raise
1st Feb 20247:00 amRNSTalking Medicines Fundraise
31st Jan 20245:32 pmRNSTotal Voting Rights
24th Jan 20247:00 amRNSPlacing to raise £400,000
15th Jan 20243:22 pmRNSHolding(s) in Company
28th Dec 20237:00 amRNSCompletion of Tranche One of the DA Fund raise
27th Dec 20237:00 amRNSDevice Authority Fund raise
29th Nov 20237:00 amRNSKonektio update
24th Nov 20237:00 amRNSInvestor Webinar Recording
21st Nov 20237:00 amRNSCompany and Portfolio Update
15th Nov 20237:00 amRNSOnline Investor Presentation and Q&A Session
8th Nov 20237:00 amRNSKonektio update
26th Sep 202312:19 pmRNSResult of GM
31st Aug 20237:00 amRNSNotice of General Meeting
16th Aug 20237:00 amRNSInterim results for the six months to 30 June 2023
10th Aug 20237:00 amRNSBoard and Management Restructuring
4th Aug 20231:33 pmRNSStatement re Share Price Movement
4th Jul 20237:00 amRNSDevice Authority convertible loan note extension
30th Jun 20235:00 pmRNSTotal Voting Rights
29th Jun 202310:09 amRNSResult of AGM and Directorate Change
28th Jun 20237:00 amRNSDevice Authority - Winner of Microsoft Award
12th Jun 202311:35 amRNSFunding facility
31st May 20237:00 amRNSResults for the year ended 31 December 2022
26th May 20237:00 amRNSKonektio Fundraise

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.